- Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address.
- Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample.
- The company’s clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods.
- The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs, to expand access to its cardiovascular testing solutions.
- Recent developments include expanded provider partnerships across the United States, finalized CMS reimbursement rates of $854 for its clinical tests, initial international expansion into India, and clinical data presentations supporting its ability to detect forms of coronary heart disease that traditional tools may miss.
Cardio Diagnostics Holdings (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators.
Questions around this news
What does Cardio Diagnostics’ cardiovascular testing platform analyze?
The release says the platform combines epigenetic and genetic biomarkers with artificial intelligence to produce cardiovascular insights from a blood sample. It is designed to consider both inherited predisposition and changes associated with lifestyle and environment, with the goal of supporting more personalized assessment of cardiovascular disease.
What reimbursement rate did the release report for the company’s clinical tests?
The release reports finalized CMS reimbursement rates of $854 for the company’s clinical tests. It also mentions expanded provider partnerships in the United States, employer partnerships, community-based programs, and initial expansion into India as part of the company’s commercialization activity.
What is epigenetics, and how does it differ from genetics?
Genetics concerns inherited DNA sequence variations. Epigenetics refers to changes that influence how genes are regulated without changing the underlying DNA sequence. Some epigenetic patterns can be associated with factors such as aging, lifestyle, or environment, though their significance depends on the specific context and how they are measured.
What does CMS reimbursement mean for a medical test?
CMS reimbursement refers to payment under programs administered by the Centers for Medicare & Medicaid Services for eligible healthcare services or tests. A reimbursement rate is a payment amount associated with a covered service; coverage and payment can depend on applicable program rules and circumstances.
At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
Cardio Diagnostics Holdings describes a platform combining epigenetic and genetic biomarkers with artificial intelligence to produce cardiovascular insights from blood samples. The company says its tests assess coronary heart disease, including forms that may not be detected by traditional methods, and do not require fasting or radiation. It reports expanding provider relationships in the United States, entering India, and establishing CMS reimbursement rates of $854 for its clinical tests. The company also cites clinical data presentations as support for the tests’ detection capabilities. Its commercialization efforts include provider networks, employer partnerships and community programs. The release frames these developments as part of the company’s effort to make cardiovascular disease prevention, detection and management more accessible and personalized.
Key takeaways
- The company’s platform combines genetic and epigenetic biomarkers with artificial intelligence to generate insights from blood samples.
- Cardio Diagnostics reports expanded U.S. provider partnerships and an initial expansion into India.
- CMS reimbursement rates for its clinical tests were finalized at $854, according to the release.
- The company says its tests are designed to detect forms of coronary heart disease that traditional methods may miss.
